Pharmaceuticals company Orchid Pharma announced Q2FY26 results Sales: Rs 194 crore against Rs 223 crore during Q2FY25, change -13%. EBITDA: Rs 15 crore against Rs 38 crore during Q2FY25, change -61%. PBT: Rs 2 crore against Rs 26 crore during Q2FY25, change -92%. PAT: Rs 2 crore against Rs 26 crore during Q2FY25, change -92%. Result PDF
Pharmaceuticals company Orchid Pharma announced H1FY25 results H1FY25 Financial Highlights: Sales reached Rs 222.7 crore, with EBITDA at Rs 37.5 crore. Cumulative sales amounted to Rs 467.1 crore, a notable 22% YoY increase compared to H1FY24. EBITDA for H1 rose to Rs 78.6 crore. Manish Dhanuka, Managing Director, Orchid Pharma said: “Our growth is a testament to disciplined operational execution and the momentum from our strategic business development initiatives like the newly launched Orchid AMS. The positive trajectory is proof of our commitment to driving sustainable, profitable growth.” Result PDF